Manages well-differentiated thyroid cancer Thyroid Suppression Test. ANDA 90097, held by Dr Reddys Labs SA. Liothyronine Sodium.
As of Nov 16, 2026, ANDA 90097 (Liothyronine Sodium), held by Dr Reddys Labs SA, was first approved by FDA on Mar 20, 2009, with 1 approved supplement and 0 published complete response letters.
Liothyronine sodium tablets are an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 20, 2009 | Original application | Approved |
| Liothyronine SodiumEQ 0.005MG BASE · tablet;oral | Liothyronine Sodium | Rx |
| Liothyronine SodiumEQ 0.025MG BASE · tablet;oral | Liothyronine Sodium | Rx |
| Liothyronine SodiumEQ 0.05MG BASE · tablet;oral | Liothyronine Sodium | Rx |
| Dec 17, 2019 | Supplement 13Labeling · Standard review | Approved | None posted |
| Mar 20, 2009 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters